Acthar SLE (Systemic Lupus Erythematosus)

Summary

This is a randomized study exploring the efficacy, safety and steroid sparing ability of two doses (40 U and 80 U) of Acthar in SLE patients with immune mediated hematologic manifestations requiring steroid use for a minimum of 2 weeks prior to screening.

Timeline

Start

2016-10

Primary completion

2019-05-22

Completion

2019-05-22

Outcome

Outcome not reported

Stopped (Enrollment): “closed in agreement of the sponsor and institution due to lack of patient accrual.”

Drugs

Indications